impact factor, citescore
logo
 

Full Papers

 

Anti-Ro/SSA antibodies in rheumatoid arthritis: Clinical and immunologic associations


I.Cavazzana, F. Franceschini, M. Quinzanini, C. Manera, N. Del Papa, W. Maglione, D. Comina, A. Radice, R.A. Sinico, R. Cattaneo

 

CER2723
2006 Vol.24, N°1
PI 0059, PF 0064
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 16539820 [PubMed]

Abstract

OBJECTIVES:
To assess the prevalence of anti-Ro/SSA in RA and to analyse clinical and serological features of anti-Ro/SSA positive patients with RA.
METHODS:
195 consecutive patients affected by RA were studied by counterimmunoelectrophoresis and ELISA for the detection of anti-Ro/SSA antibodies. Anti-Ro were found in 12 patients, with a prevalence of 6%. These 12 patients were pooled with other 15 patients known to have anti-Ro/SSA antibodies and RA, in order to evaluate their clinical and laboratory features.
RESULTS:
Anti-Ro positive patients showed a common pattern of joint involvement at onset and a comparable progression of disease compared to anti-Ro negative subjects. In addition, extra-articular manifestations (such as xerophthalmia, xerostomia, scleritis, oral ulcers and amyloidosis) and peculiar autoantibody profile (hypergammaglobulinemia, anti-dsDNA and AMA) were found significantly associated to anti-Ro/SSA positivity. Even though DMARDs withdrawals were more frequently detected in anti-Ro/SSA patients, especially when using gold salts, no statistical difference between the two groups was detected. In addition, anti-TNFα treatment did not cause further progression of autoimmunity neither on laboratory nor on clinical ground.
CONCLUSIONS:
Anti-Ro/SSA can be detected in about 6% of patients affected by RA. These patients presented a peculiar clinical picture characterised by extra-articular manifestations some of which are known to be anti-Ro/SSA correlated, while others are more disease-specific (amyloidosis, episcleritis). Anti-Ro/SSA are significantly associated with other autoantibodies not specific for RA such as anti-dsDNA and AMA. Treatment with anti-TNF drugs did not cause further progression of autoimmunity neither on laboratory nor on clinical ground.

Rheumatology Article